These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9228265)

  • 1. Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis.
    Filippi M; Yousry T; Rocca MA; Fesl G; Voltz R; Comi G
    Acta Neurol Scand; 1997 Jun; 95(6):331-4. PubMed ID: 9228265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans.
    Rovaris M; Mastronardo G; Prandini F; Bastianello S; Comi G; Filippi M
    J Neurol Sci; 1999 Apr; 164(2):148-52. PubMed ID: 10402026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging.
    Silver NC; Good CD; Barker GJ; MacManus DG; Thompson AJ; Moseley IF; McDonald WI; Miller DH
    Brain; 1997 Jul; 120 ( Pt 7)():1149-61. PubMed ID: 9236628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.
    Filippi M; Yousry T; Campi A; Kandziora C; Colombo B; Voltz R; Martinelli V; Spuler S; Bressi S; Scotti G; Comi G
    Neurology; 1996 Feb; 46(2):379-84. PubMed ID: 8614498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.
    Filippi M; Rovaris M; Capra R; Gasperini C; Yousry TA; Sormani MP; Prandini F; Horsfield MA; Martinelli V; Bastianello S; Kühne I; Pozzilli C; Comi G
    Brain; 1998 Oct; 121 ( Pt 10)():2011-20. PubMed ID: 9798753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions.
    Uysal E; Erturk SM; Yildirim H; Seleker F; Basak M
    AJR Am J Roentgenol; 2007 Mar; 188(3):697-702. PubMed ID: 17312056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
    Barkhof F; Scheltens P; Frequin ST; Nauta JJ; Tas MW; Valk J; Hommes OR
    AJR Am J Roentgenol; 1992 Nov; 159(5):1041-7. PubMed ID: 1414773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis.
    Filippi M; Rovaris M; Gasperini C; Capra R; Bastianello S; Kuhne I; Yousry TA
    J Neuroimaging; 1998 Apr; 8(2):88-93. PubMed ID: 9557146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis.
    Gasperini C; Paolillo A; Rovaris M; Yousry TA; Capra R; Bastianello S; Filippi M
    Magn Reson Imaging; 2000 Jul; 18(6):761-3. PubMed ID: 10930786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis.
    Filippi M; Barkhof F; Bressi S; Yousry TA; Miller DH
    Mult Scler; 1997 Aug; 3(4):226-30. PubMed ID: 9372504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis.
    Filippi M; Capra R; Campi A; Colombo B; Prandini F; Marcianò N; Gasparotti R; Comi G
    J Neurol Neurosurg Psychiatry; 1996 May; 60(5):526-30. PubMed ID: 8778257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting new lesion formation in multiple sclerosis: the relative contributions of monthly dual-echo and T1-weighted scans after triple-dose gadolinium.
    Filippi M; Mastronardo G; Rocca MA; Capra R; Gasperini C; Rovaris M; Bastianello S; Comi G
    Eur Neurol; 1998 Oct; 40(3):146-50. PubMed ID: 9748672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis.
    Filippi M; Mastronardo G; Bastianello S; Rocca MA; Rovaris M; Gasperini C; Pozzilli C; Comi G
    J Neurol Sci; 1998 Jul; 159(1):94-101. PubMed ID: 9700710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of Unenhanced MRI in the Detection of New Brain Lesions in Multiple Sclerosis.
    Eichinger P; Schön S; Pongratz V; Wiestler H; Zhang H; Bussas M; Hoshi MM; Kirschke J; Berthele A; Zimmer C; Hemmer B; Mühlau M; Wiestler B
    Radiology; 2019 May; 291(2):429-435. PubMed ID: 30860448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging.
    Wolansky LJ; Finden SG; Chang R; Conigliari M; Lee HJ; Shaderowsky PD; Cook SD
    Clin Imaging; 1998; 22(6):385-92. PubMed ID: 9876905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging.
    Tourdias T; Roggerone S; Filippi M; Kanagaki M; Rovaris M; Miller DH; Petry KG; Brochet B; Pruvo JP; Radüe EW; Dousset V
    Radiology; 2012 Jul; 264(1):225-33. PubMed ID: 22723563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis.
    Lai M; Hodgson T; Gawne-Cain M; Webb S; MacManus D; McDonald WI; Thompson AJ; Miller DH
    J Neurol Neurosurg Psychiatry; 1996 Mar; 60(3):339-41. PubMed ID: 8609517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.
    Thorpe JW; Kidd D; Moseley IF; Kenndall BE; Thompson AJ; MacManus DG; McDonald WI; Miller DH
    Neurology; 1996 Feb; 46(2):373-8. PubMed ID: 8614497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients.
    Gasperini C; Pozzilli C; Bastianello S; Koudriavtseva T; Colleluori A; Millefiorini E; Thompson AJ; Horsfield MA; Galgani S; Bozzao L; Fieschi C
    Acta Neurol Scand; 1997 Apr; 95(4):201-7. PubMed ID: 9150809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.